Hepadnaviridae infectious disease

This early-stage trial tests a new vaccine called AVX70371, designed to treat chronic hepatitis B by training the immune system to fight the virus. It involves 16 healthy adults aged 18 to 40 to check for safety and immune responses. The study is not yet testing if it works again…

This study looks at two antiviral drugs, TAF and TDF, in pregnant women with chronic hepatitis B. It aims to see which one better controls the virus and keeps the mother's liver healthy without harming the baby. About 816 women in early or middle pregnancy will take one of the dr…

This study tests a drug called tenofovir alafenamide (TAF) in 150 children and teens with chronic hepatitis B. Half receive TAF and half receive a placebo for 24 weeks. Researchers are checking how safe the drug is, how the body processes it, and whether it lowers virus levels. T…

This early-stage trial tests a therapeutic vaccine called ISA104 in 24 people with chronic hepatitis B who are already on antiviral drugs. The goal is to see if the vaccine is safe and can boost the immune system to better fight the virus. Participants will receive either ISA104 …

This study tests whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. The 84 participants will take entecavir before starting their…

This study tests a new drug called bepirovirsen in 153 people who have both HIV and chronic hepatitis B and are already on HIV treatment. The goal is to see if bepirovirsen can clear the hepatitis B virus from the body better than a placebo. Participants will continue their regul…

This study tests a new drug called AHB-137 in 86 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if AHB-137 can clear the hepatitis B surface antigen from the blood, which would mean the virus is under control and patients might be …

This Phase 2 trial tests an experimental drug called AHB-137 in 105 adults with chronic hepatitis B who have not been treated before. The goal is to see if the drug can clear the hepatitis B surface antigen and lower the virus to undetectable levels, potentially leading to a func…

This study tests an injection called AHB-137 in 20 adults with chronic hepatitis B who are already on standard antiviral pills. The goal is to see if the drug can lower or eliminate hepatitis B surface antigen (HBsAg) and viral DNA, potentially leading to a functional cure. Parti…

This phase 3 trial tests an experimental drug called AHB-137 in 577 adults with HBeAg-negative chronic hepatitis B who are already on standard antiviral pills. Participants receive weekly injections of AHB-137 or a placebo for a set period, then stop all hepatitis B treatment. Th…

This study looks at switching kidney or liver transplant patients with chronic hepatitis B to a drug called tenofovir alafenamide (TAF). The goal is to see if TAF is safer for the kidneys, controls the virus well, and is easier for patients to stick with. The study involves 52 ad…

This study is testing a drug called pradefovir mesylate in 400 adults with chronic hepatitis B. The goal is to see how well it lowers the virus and how safe it is in everyday medical practice, not just in a strict research setting. Participants are being followed for up to 65 wee…

This study tests two antiviral medications, TAF and TDF, in 200 pregnant women with chronic hepatitis B. The goal is to see which drug better prevents passing the virus to the baby and causes fewer birth defects or side effects. Participants take the drug daily during pregnancy a…

This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…

This study tests a combination of two drugs, atezolizumab and bevacizumab, in 51 people with advanced liver cancer who also have chronic hepatitis B. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks, a…

This pilot study tests whether adding a PD-1 antibody (sintilimab) and pegylated interferon to standard antiviral therapy can help people with chronic hepatitis B lose the hepatitis B surface antigen (HBsAg), a key step toward a functional cure. The trial will enroll 45 adults wh…

This study looks at whether a special team of doctors and nurses can treat adults with suspected infections at home, instead of sending them to the hospital. About 500 people will be randomly assigned to either standard hospital care or home-based care from a mobile response team…

This study looks at 260 chronic hepatitis B patients who stopped their antiviral medication and then had a flare-up. They are switched to a drug called tenofovir alafenamide (TAF) to see if it can control the virus and improve liver health. The goal is to measure how many patient…

This study tested an antiviral drug called tenofovir in children aged 2 to 12 with chronic hepatitis B. The goal was to see if the drug could lower the amount of virus in their blood compared to a placebo. The trial involved 90 children and measured safety and effectiveness over …

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. T…

This Phase 2 trial tests whether a new injection called BW-20507, combined with pegylated interferon alfa, can help people with chronic hepatitis B stop their daily antiviral medication (NUCs). About 209 adults with hepatitis B will receive the combination for 48 weeks. The main …

This study was designed to test ARC-520, an experimental RNAi drug, in people with chronic hepatitis B who were already taking standard antiviral medications. The goal was to see if adding ARC-520 could lower hepatitis B surface antigen levels more effectively. However, the trial…

This study looks at whether a combination of four herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata, and ascorbic acid) plus the drug tenofovir can help control hepatitis B over the long term. The treatment aims to strengthen the immune system and reduce virus l…

This Phase 2 trial tests whether adding TQ-A3334 tablets to standard nucleoside analog drugs can better control chronic hepatitis B. About 116 adults with the infection will receive either the combination or a placebo plus standard drugs. The main goal is to see if the combinatio…

This study tests two experimental injections, HT-101 and HT-102, in 60 adults with chronic hepatitis B who are already on standard antiviral therapy. The goal is to see if the combination can lower hepatitis B virus levels to undetectable and help the immune system control the in…

This study tests a drug called Tenofovir Amibufenamide (TMF) in 200 adults with chronic hepatitis B who have normal liver enzyme levels (ALT). The goal is to see if TMF can lower the virus to undetectable levels and possibly clear the hepatitis B surface antigen. Participants are…

This study tests whether adults with chronic hepatitis B who have no liver scarring can safely stop taking antiviral drugs. The 140 participants have undetectable virus levels and negative HBeAg status. Researchers will monitor for viral relapse and liver problems over time.

This study tests a new medication called hepenofovir fumarate (HTS) for people with chronic hepatitis B, a long-term liver infection. About 1,444 adults aged 18-65 who have not been treated before (or stopped treatment at least 6 months ago) will take one of three doses of HTS or…

This early-stage trial tests a new vaccine called TVAX-008 in 20 adults with chronic hepatitis B who have very low levels of the virus. The goal is to see if the vaccine can safely boost the body's immune response, potentially helping control the infection. Participants will be m…

This Phase 2 trial tests an injection called TVAX-008 in 80 adults with chronic hepatitis B who are already on antiviral pills. Half get TVAX-008 plus their usual medication, half get a placebo plus their usual medication, for 24 weeks. The goal is to see if TVAX-008 can make the…

This early-stage trial tests two new injections (HT-101 and HT-102) in 86 people with chronic hepatitis B. Participants receive the shots every 4 weeks, along with standard antiviral pills. The main goal is to check safety and how the body processes the drugs, while also looking …

This Phase 2 trial tests an injection called TVAX-008 in 48 adults with chronic hepatitis B who have low levels of the virus. Half receive the drug, half a placebo, to see if it can clear a key virus marker (HBsAg) safely. The study is double-blind and already finished enrolling.

This phase 2 study tests whether adding the experimental drug BRII-835 to standard pegylated interferon can help people with chronic hepatitis B lose the virus surface antigen (HBsAg), a key marker of infection. Eighty-six adults on stable antiviral therapy will receive either in…

This study is testing whether adding a blood test called the GAAD score to regular ultrasound scans can improve the detection of liver cancer in people at high risk, such as those with cirrhosis or chronic hepatitis. About 2,100 participants will get both tests every six months f…

This study is testing whether a new blood test score, called GAAD, can detect liver cancer earlier in people with chronic liver disease. The GAAD score combines a person's gender, age, and two blood markers (AFP and PIVKA-II). Researchers will compare the GAAD score to standard u…

This study is testing a new blood test called Oncoguard Liver to see how well it detects liver cancer (hepatocellular carcinoma) in people at increased risk, such as those with cirrhosis or hepatitis B. About 3,000 participants will provide a blood sample and undergo imaging like…

This phase 3 trial tests whether giving antiviral medication to pregnant women with hepatitis B and their newborns can prevent the virus from passing to the baby. The study involves 450 women and their infants in Africa. The goal is to find a safe and effective way to reduce moth…

This study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study looks at how chronic hepatitis B virus (HBV) infection affects natural killer (NK) cells, which are key immune cells that fight infections. Researchers will collect blood samples from 80 people with HBV and compare them to healthy donors. The goal is to understand why …

This study follows about 360 people with chronic hepatitis B who had a good response to the experimental drug bepirovirsen in earlier trials. No new drug is given; researchers simply monitor whether the response lasts over time. Participants may or may not continue standard antiv…

This study looks at 300 patients with advanced liver scarring (cirrhosis) caused by hepatitis B or alcohol who have shown signs of getting better. Researchers want to understand what predicts this improvement and how long it lasts. The goal is to create clearer guidelines for whe…

This study gives a single dose of bepirovirsen to 32 adults with hepatitis B, some with kidney disease and some healthy. Researchers measure how much drug gets into the blood and how long it stays. The goal is to see if kidney problems change drug levels, which could affect futur…

This study was designed to collect information on pregnancy and baby outcomes in women who received the PREHEVBRIO hepatitis B vaccine around the time of conception or during pregnancy. The goal was to watch for any safety concerns, such as miscarriage or birth defects. However, …

This study aimed to see if a computer could learn to predict how long a patient would stay in a home hospital program. Researchers planned to use data from past patients to train the computer. However, the study was withdrawn before any patients were enrolled, so no results are a…

This study follows 54 people with chronic hepatitis B who stop taking their antiviral medication after at least three years. Researchers will closely monitor their immune system and virus levels to see what happens during a flare. The goal is to learn whether a controlled flare m…

This study looks at how the immune system behaves in people with chronic hepatitis B. Researchers are measuring different immune cells and signals to understand why some people control the virus better than others. 201 adults already enrolled in a larger hepatitis B study are pro…

This study looks at how the immune system responds to chronic hepatitis B infection. Researchers will analyze blood samples from 40 adults already enrolled in larger treatment trials. The goal is to understand why some people respond better to therapy and how the disease progress…

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepat…

This study follows 60 cancer patients who have a hidden form of hepatitis B (occult infection) and are receiving immunotherapy. The goal is to see how often the virus becomes active again, which could cause liver problems. Researchers will monitor blood tests and immune responses…

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This observational study follows 11 patients with chronic hepatitis B and delta coinfection and liver cirrhosis who are already receiving the antiviral drug Bulevirtide. Researchers want to see if suppressing the virus reduces portal hypertension—a dangerous buildup of pressure i…